Pfizer (PFE)
(Real Time Quote from BATS)
$28.18 USD
-0.09 (-0.32%)
Updated May 9, 2024 03:28 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Price, Consensus and EPS Surprise
PFE 28.18 -0.09(-0.32%)
Will PFE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PFE
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Pfizer (PFE) is a Strong Momentum Stock
Here's Why Pfizer (PFE) is a Strong Momentum Stock
Company News for May 2, 2024
Other News for PFE
3 Profitable Dividend Stocks to Buy at Near-Lows
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
Unusually active option classes on open May 9th
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Second Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial